Title A Phase 1 Study of Evaluate the Safety, Tolerability and Efficacy of MK-8353 (formerly SCH 900353) in Subjects with Advanced Solid Tumors (Protocol No.001) formerly P06203
Contact ADiRaddo
Principal Investigator Alex Adjei, MD PhD
Study Number 182110
Phase1
Summary The purpose of this study is to find the highest dose of SCH 900353 that can be given without causing severe side effects. In the second part of the study, the purpose will be to find out what effects (good and bad) SCH 900353 has on you and your type of colorectal cancer or melanoma.
Eligibility
- Adult patients (18 years and older) with a diagnosis of advanced solid tumors.
- Patients must have adequate organ function.
- Patients must be able to swallow, retain, and absorb oral medications and oral nutrition.
- Patients must not be pregnant or breastfeeding.